Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Nature Reviews. Clinical Oncology|October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offsSharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2026
Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein DegradationChen Song, Qi Liu, Tingjian Wang, et al.
The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.
Implementation Science : IS|January 6, 2026
A cluster randomised controlled trial, process and economic evaluation of two large-scale quality improvement interventions embedded with a national clinical audit to improve the care for young adults with type 2 diabetes (EQUIPD2): study protocolMichael Sykes, Bethan Copsey, Tracy Finch, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Molecular Biology of the Cell|August 9, 2013
Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular fluxMary M Buschmann, Le Shen, Harsha Rajapakse, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal EvolutionMin Tang, Rui Zhao, Helgi van de Velde, et al.
Blood|October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
Cancer|October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myelomaJames R Berenson, Sundar Jagannath, Bart Barlogie, et al.
Pageof 11